MPN Advocacy and Education International is being supported in part by the following partners who have contributed to educational programs and projects for MPN patients, caregivers, and physicians. It is our goal to strengthen collaborations, provide a greater understanding of how drugs are developed and approved and form partnerships with all of our constituents with the shared goal and purpose of providing access to information, treatments, and quality care.
Incyte discovered and developed the JAK1 and JAK2 inhibitor JAKAFI® (ruxolitinib), which is the first medicine approved by the FDA to treat certain types of myelofibrosis and to treat people with polycythemia vera (PV) who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. [click here to learn more about JAKAFI]. JAKAFI is the first and only medicine approved for treatment of these patients.
If you have been prescribed JAKAFI, IncyteCARES may be able to help with Copay Assistance for your JAKAFI treatment. [Click here to learn more about the IncyteCARES assistance.]
Incyte is a strong supporter of physician and patient education programs, as well as advocacy projects, including the nationwide launch of Myelofibrosis Awareness Day. www.incyte.com
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, for the potential treatment of hematologic myeloid malignancies. Recent data from a Phase 2 clinical trial of imetelstat in patients with essential thrombocythemia showed hematologic and molecular responses that suggest a relatively selective inhibition of the malignant progenitor cells responsible for the underlying disease. Geron believes this potentially disease-modifying effect may be applicable to other hematologic myeloid malignancies. Imetelstat is currently being studied in patients with myelofibrosis. www.geron.com
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising function and ultimately leading to organ failure. www.promedior.com
CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Their therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers. www.ctibiopharma.com
PharmaEssentia is a global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia, hepatitis, and other diseases. PharmaEssentia is developing ropeginterferon alfa-2b, a novel, long-acting, mono-pegylated proline interferon for both PV and ET. It is uniquely administered once every two weeks, offering improved tolerability and convenience, and may offer the potential for disease modification. A Phase III clinical trial for ropeginterferon alfa-2b in PV was recently completed, and the company plans to present data to the U.S. FDA for approval. If approved, ropeginterferon alfa-2b is expected to be the first interferon approved for PV worldwide and the only approved first-line treatment for PV in the U.S. www.pharmaessentia.com or www.ropeginf.com
Impact Biomedicines, Inc. (Impact) is pioneering the development of therapies for patients with life-threatening malignancies. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around our product candidate, fedratinib, a potent and highly selective JAK2 kinase inhibitor, which is being developed for the treatment of myelofibrosis (MF) and other refractory blood cancers. Impact was formed in 2016 as a stand-alone spinout from Sanofi and was assigned full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases. impactbiomedicines.com